[ad_1] HAIKOU, China, Sept. 22, 2024 /PRNewswire/ — A report from Hainan International Media Center (HIMC): On September 21, the 14th China International Digital Publishing Expo opened in Haikou, capital city of south China’s Hainan Province. […]
Trending Stories
Late Stage Asset Management Investors Have Opportunity to Lead The Late Stage Asset Management, LLC Securities Fraud Lawsuit
[ad_1] NEW YORK, Sept. 22, 2024 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of Pre-IPO shares through funds issued by Late Stage Asset Management, LLC between March 2019 and March […]
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit
[ad_1] NEW YORK, Sept. 22, 2024 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Indivior PLC (NASDAQ: INDV) between February 22, 2024 and July 8, […]
HandicapMD.com Revolutionizes Access to Handicap Placards in New York
[ad_1] HandicapMD.com, a leader in telehealth services specializing in disability evaluations, is making it easier than ever for New Yorkers to obtain a handicap placard online. HEMPSTEAD, N.Y., Sept. 22, 2024 /PRNewswire/ — With a […]
Henlius et Intas reçoivent un avis favorable du CHMP pour HETRONIFLY® (approuvé sous le nom de HANSIZHUANG en Chine) sur les marchés européens en tant que traitement de première intention pour les patients adultes atteints d’un cancer du poumon à petites cellules au stade étendu USA – Français USA – English USA – español USA – Deutsch
[ad_1] – HANSIZHUANG ® (serplulimab) a été le premier anticorps monoclonal anti-PD-1 approuvé pour le traitement de première intention du CPPC au stade étendu – HETRONIFLY® (serplulimab) devrait devenir le premier anticorps monoclonal anti-PD-1 disponible […]
